公开(公告)号：EP4053277A1

公开(公告)日：2022-09-07

申请号：EP21213766.5

申请日：2016-12-26

申请人： Novartis AG ,  Intellia Therapeutics, Inc.

发明人： BOITANO, Anthony Edward ,  COOKE, Michael ,  KLICKSTEIN, Lloyd B. ,  LESCARBEAU, Reynald ,  MICKANIN, Craig Stephen ,  MULUMBA, Kabungo ,  POLICE, Seshidhar Reddy ,  SNEAD, Jennifer ,  STEVENSON, Susan C. ,  STEWART, Morag ,  YANG, Yi

IPC分类号： C12N15/113

摘要： The present invention is directed to genome editing systems, reagents and methods for the treatment of hemoglobinopathies.

公开(公告)号：EP3229907A1

公开(公告)日：2017-10-18

申请号：EP15816531.6

申请日：2015-12-04

申请人： Novartis AG

发明人： KORTEBEIN, Patrick ,  ROOKS, Daniel ,  KLICKSTEIN, Lloyd B. ,  ROUBENOFF, Ronenn ,  GLASS, David ,  TRIFILIEFF, Estelle ,  PAPANICOLAOU, Dimitris

IPC分类号： A61P21/00 ,  A61K39/395

CPC分类号： C07K16/2863 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/54 ,  A61K2039/545 ,  C07K2317/21 ,  C07K2317/76 ,  C07K2317/90

摘要： The present invention relates to myostatin or activin antagonists, dose regimen and pharmaceutical compositions thereof, for the treatment of sarcopenia, in particular age-related sarcopenia. Especially, the myostatin or activin antagonist bimagrumab was found to be beneficial in the treatment of older adults with sarcopenia with respect to increasing their skeletal muscle strength and function.

摘要翻译： 本发明涉及肌肉生长抑制素或激活素拮抗剂，其剂量方案及其药物组合物，用于治疗肌肉减少症，特别是与年龄有关的肌肉减少症。 特别是，发现肌肉生长抑制素或激活素拮抗剂bimagrumab在治疗患有肌肉减少症的老年人方面有利于提高其骨骼肌强度和功能。

公开(公告)号：EP3373927A1

公开(公告)日：2018-09-19

申请号：EP16795436.1

申请日：2016-11-09

申请人： Novartis AG

发明人： KLICKSTEIN, Lloyd B. ,  ROUBENOFF, Ronenn ,  FEIGE, Jerome ,  TRIFILIEFF, Estelle ,  HAKATEYAMA, Shinji

IPC分类号： A61K31/282 ,  A61P35/00 ,  A61K31/436 ,  A61K39/395

CPC分类号： A61K31/282 ,  A61K31/436 ,  A61K39/3955 ,  A61K2300/00

摘要： The present invention relates to myostatin antagonists, for the treatment of cancer cachexia, and cancer cachexia due to chemotherapeutic treatment Especially, the myostatin antagonist bimagrumab was found to be beneficial in the treatment of cancer cachexia by reducing body weight loss. The present invention also relates to combinations and uses of a myostatin antagonist and an mTOR inhibitor for treating cancer cachexia by reducing, maintaining or increasing body weight loss or for use in treating age-related conditions.

公开(公告)号：EP3233083A1

公开(公告)日：2017-10-25

申请号：EP15813923.8

申请日：2015-12-08

申请人： Novartis AG

发明人： BADMAN, Michael ,  KLICKSTEIN, Lloyd B. ,  LAFFITTE, Bryan

IPC分类号： A61K31/4748 ,  A61K31/497 ,  A61K31/506 ,  A61P1/16 ,  A61P1/00

CPC分类号： A61K31/439 ,  A61K31/422 ,  A61K31/426 ,  A61K31/4748 ,  A61K31/497 ,  A61K31/506

摘要： The invention provides methods for modulating the activity of farnesoid X receptors (FXRs) using compounds of Formula (I) or (II). In particular, the invention provides for the use of compounds of Formula (I) or (II), or a stereoisomer, enantionmer or pharmaceutically acceptable salt thereof, for treating or preventing liver and gastrointestinal diseases.

摘要翻译： 本发明提供了使用式（I）或（II）化合物调节法尼醇X受体（FXR）活性的方法。 特别地，本发明提供了式（I）或（II）的化合物或其立体异构体，对映异构体或药学上可接受的盐用于治疗或预防肝和胃肠疾病的用途。

公开(公告)号：EP2766033A2

公开(公告)日：2014-08-20

申请号：EP12794776.0

申请日：2012-10-12

申请人： Novartis AG

发明人： CONG, Feng ,  HAO, Huaixiang ,  KLICKSTEIN, Lloyd B. ,  KWONG, Rou-Fun ,  TAYLOR, Ann ,  XIE, Yang

IPC分类号： A61K38/17 ,  A61K39/395

CPC分类号： C07K16/40 ,  A61K31/40 ,  A61K38/53 ,  A61K39/3955 ,  A61K45/06 ,  C12N9/93 ,  C12Y603/02019 ,  A61K2300/00

摘要： The transmembrane E3 ubiquitin ligases ZNRF3 and RNF43 are negative regulators of &bgr;-catenin and the Wnt signaling pathway in eukaryotic cells. The activity of ZNRF3 can be modulated by antibody binding to its extracellular domain, thus causing an increase in Wnt signaling. The ZNRF3 antagonizing antibodies can be used to treat diseases with low Wnt signaling, such as short bowel syndrome, osteoporosis, diabetes, neurodegenerative diseases, and mucositis. In addition, the antagonizing antibodies of the invention can be used to enhance Wnt signaling for tissue repair and wound healing.

摘要翻译： 跨膜E3泛素连接酶ZNRF3和RNF43是真核细胞中的β-联蛋白和Wnt信号通路的负调节物。 ZNRF3的活性可通过抗体结合其细胞外结构域调节，从而导致Wnt信号传导的增加。 ZNRF3拮抗抗体可用于治疗低Wnt信号传导疾病，如短肠综合征，骨质疏松症，糖尿病，神经变性疾病和粘膜炎。 此外，本发明的拮抗性抗体可用于增强组织修复和伤口愈合的Wnt信号传导。

公开(公告)号：EP2753313A1

公开(公告)日：2014-07-16

申请号：EP12758966.1

申请日：2012-09-06

申请人： Novartis AG

发明人： TAYLOR, Ann ,  KLICKSTEIN, Lloyd B. ,  THAKUR, Jeewan

IPC分类号： A61K9/48 ,  A61K31/4196 ,  A61P5/26 ,  A61P15/08 ,  A61P35/00

CPC分类号： A61K31/4196 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

摘要： The present invention relates to low-dose pharmaceutical compositions comprising the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, as the active ingredient in a suitable carrier. The present invention also relates to a process for their preparation and to their use as medicaments.

公开(公告)号：EP2766033B1

公开(公告)日：2019-11-20

申请号：EP12794776.0

申请日：2012-10-12

申请人： Novartis AG

发明人： CONG, Feng ,  HAO, Huaixiang ,  KLICKSTEIN, Lloyd B. ,  KWONG, Rou-Fun ,  TAYLOR, Ann ,  XIE, Yang

IPC分类号： A61K38/17 ,  A61K39/395

公开(公告)号：EP2753312A1

公开(公告)日：2014-07-16

申请号：EP12758965.3

申请日：2012-09-06

申请人： Novartis AG

发明人： TAYLOR, Ann ,  KLICKSTEIN, Lloyd B.

IPC分类号： A61K9/48 ,  A61K31/4196 ,  A61P5/26 ,  A61P15/08

CPC分类号： A61K31/4196 ,  A61K9/4833 ,  A61K9/485 ,  A61K9/4858 ,  A61K9/4866

摘要： This invention relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile. The present invention further relates to a method of increasing testosterone levels and treating hypogonadism and related diseases with the aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile in a particular dosing regimen. The invention also relates to pharmaceutical compositions comprising said aromatase inhibitor 4,4'-[fluoro-(1-H-1,2,4-triazol-1-yl)methylene]bisbenzonitrile, optionally in combination with other active ingredients. Furthermore, the present invention relates to kits comprising said pharmaceutical compositions together with instructions how to administer them.

公开(公告)号：EP2207807A2

公开(公告)日：2010-07-21

申请号：EP08844727.1

申请日：2008-10-31

申请人： Novartis AG

发明人： ETEMAD-GILBERTSON, Bijan ,  GUILD, Braydon Charles ,  KEATING, Mark Taylor ,  KIM, Yong-In ,  KLICKSTEIN, Lloyd B. ,  MIKHAILOV, Dmitri ,  MILIK, Mariusz ,  ROGUSKA, Michael ,  SPLAWSKI, Igor ,  ZHAO, Kehao

IPC分类号： C07K16/18 ,  A61K39/395 ,  C07K7/00

CPC分类号： C07K16/18 ,  C07K2317/21 ,  C07K2317/55 ,  C07K2317/565 ,  C07K2317/92

摘要： Compositions that bind to C3b epitopes and methods of using the compositions are described herein.